Prostaglandin A 2 (PGA 2 ), an experimental chemotherapeutic agent, causes growth arrest associated with decreased cyclin D1 expression in several cancer cell lines. Here, using human non-small-cell lung carcinoma H1299 cells, we investigated the mechanisms whereby PGA 2 down-regulates cyclin D1 expression. Transcription rates of the cyclin D1 gene, studied using a cyclin D1 promoter-luciferase construct and nuclear run-on assays, were not affected by PGA 2 treatment. Instead, the cyclin D1 mRNA was rendered unstable after exposure to PGA 2 . Since the stability of labile mRNA is modulated through binding of proteins to specific mRNA sequences, we sought to identify protein(s) recognizing the cyclin D1 mRNA. In electrophoretic mobility-shift assays using radiolabeled RNA probes derived from different regions of cyclin D1 mRNA, we observed that (i) lysates prepared from PGA 2 -treated cells exhibited enhanced protein-cyclin D1 RNA complex formation; (ii) the kinetics of complex formation correlated closely with that of cyclin D1 mRNA loss; and (iii) binding occurred within a 390-base cyclin D1 3 untranslated region (UTR) (K12). This binding activity could be cross-linked, revealing proteins ranging from 30 to 47 kDa. The RNA-binding protein AUF1, previously associated with the degradation of target mRNAs, bound cyclin D1 mRNA, because anti-AUF1 antibodies were capable of supershifting or immunoprecipitating cyclin D1 mRNA-protein complexes. Finally, insertion of K12 in the 3UTR of reporter genes markedly reduced the expression and half-life of the resulting chimeric mRNAs in transfected, PGA 2 -treated cells. Our data demonstrate that PGA 2 down-regulates cyclin D1 expression by decreasing cyclin D1 mRNA stability and implicates a 390-base element in the 3UTR in this regulation.Progression of eucaryotic cells through the division cycle is a highly ordered process involving the sequential activation of cyclin-dependent kinases (cdks) (22,37). This process is regulated in large part through their interaction with specific cyclins, which function during different phases of the cell cycle. D-type cyclins and cyclin D1 in particular play a critical role in regulating G 1 progression (4, 43, 54) as cyclin D1-cdk4 complexes phosphorylate and thereby inactivate the retinoblastoma protein, a critical event required for G 1 -S transition (60). Cyclin D1 is present in low abundance in quiescent cells, but it rapidly accumulates after stimulation with serum or mitogens. Inhibition of cyclin D1 expression prevents transition of cells from G 1 into S phase, while ectopic expression of cyclin D1 shortens the G 1 interval in many cell types (40,43,45,46). Although cyclin D1 levels remain relatively constant in normally growing cells, withdrawal of serum results in the rapid disappearance of the protein as cells enter a state of quiescence (56). In addition to serum withdrawal, treatment of cells with other agents known to induce growth arrest (e.g., retinoic acid) likewise results in reduced cyclin D1 expression (31). Support fo...